TITLE

Carvedilol was more effective than metoprolol tartrate for lowering mortality in chronic heart failure: COMMENTARY

AUTHOR(S)
Furberg, Curt D.; Psaty, Bruce M.
PUB. DATE
January 2004
SOURCE
ACP Journal Club;Jan/Feb2004, Vol. 140 Issue 1, p5
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This article focuses on a study regarding comparison of drugs carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure, published in the 2003 issue of the journal "Lancet." The treatment of chronic heart failure is a crowded field with multiple choices, both between and within drug classes. In placebo-controlled trials in heart failure patients, carvedilol and metoprolol controlled release/extended release reduce mortality to a similar extent. The findings of the study contradict this expectation, and the investigators conclude that carvedilol extends survival more so than metoprolol.
ACCESSION #
12104531

 

Related Articles

  • Carvedilol was more effective than metoprolol tartrate for lowering mortality in chronic heart failure.  // ACP Journal Club;Jan/Feb2004, Vol. 140 Issue 1, p5 

    This article focuses on a study regarding comparison of drugs carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure, published in the 2003 issue of the journal "Lancet." Patients were allocated to twice-daily target doses of carvedilol or metoprolol. Main outcome...

  • More help for patients with less severe heart failure. Bossenbroek, Kelly; Mounsey, Anne L. // Clinician Reviews;Nov2011, Vol. 21 Issue 11, p12 

    The article discusses the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF) which is designed to assess the efficacy of eplerenone on patients with less severe disease. The study was participated by 2, 737 patients who received either eplerenone or...

  • Achieving optimal beta1-blockade with metoprolol CR/Zok. Wikstrand, J. // Basic Research in Cardiology;Nov2000 Supplement 1, Vol. 95, pI46 

    The metoprolol CR/Zok is a multi-unit formulation containing metoprolol succinate controlled release (CR/Zok) in the form of individual drug delivery units (microcapsules). Each microcapsule acts as a diffusion cell and is designed to deliver metoprolol succinate at a near constant rate for...

  • In a Subgroup of High-Risk Asians, Telmisartan Was Non-Inferior to Ramipril and Better Tolerated in the Prevention of Cardiovascular Events. Dans, Antonio L.; Koon Teo; Gao, Peggy; Jyh-Hong Chen; Kim Jae-Hyung; Yusoff, Khalid; Chaitraphan, Suphachai; Zhu, Jun; Liu Lisheng; Yusuf, Salim // PLoS Clinical Trials;Dec2010, Vol. 7 Issue 12, Special section p1 

    Background and Objectives: Results of the recently published ONTARGET study (The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial) showed that telmisartan (80 mg/day) was non-inferior to ramipril (10 mg/ day) in reducing cardiovascular events. Clinicians in Asia...

  • PROACTIVE: Pioglitazone increased incidence of HF.  // Cardiology Today;Jan2008, Vol. 11 Issue 1, p13 

    The article discusses research being done on the link between pioglitazone and heart failure. It references a study by Erland Erdmann and colleagues, published in "Diabetes Care." The study included 5,238 patients with preexisting cardiovascular disease (CVD) and type 2 diabetes. Patients who...

  • A Novel Method to Adjust Efficacy Estimates for Uptake of Other Active Treatments in Long-Term Clinical Trials. Simes, John; Voysey, Merryn; O'Connell, Rachel; Glasziou, Paul; Best, James D.; Scott, Russell; Pardy, Christopher; Byth, Karen; Sullivan, David R.; Ehnholm, Christian; Keech, Anthony // PLoS Clinical Trials;Jan2010, Vol. 7 Issue 1, Special section p1 

    Background: When rates of uptake of other drugs differ between treatment arms in long-term trials, the true benefit or harm of the treatment may be underestimated. Methods to allow for such contamination have often been limited by failing to preserve the randomization comparisons. In the...

  • Statins equivalent for CVD prevention.  // Journal of Family Practice;May2006, Vol. 55 Issue 5, p381 

    The article presents information on the research conducted on the benefits of stains to prevent a cardiovascular disease (CVD) with various statins pravastatin or Pravachol, simvastatin or Zocor and atorvastatin or Liptor. 1000 participants were included which evaluated for one year and only...

  • JUPITER Subgroup Analysis Provides Convincing Evidence for Statin Therapy as Primary Prevention for CV Events in Older Individuals.  // MD Conference Express;Nov2009, p22 

    The article highlights the findings of JUPITER subgroup analysis trial, presented by Robert Glynn of Brigham's and Women's Hospital in Boston, Massachusetts. It is stressed that the clinical trial was aimed to evaluate the effectiveness of rosuvastatin and placebo in the reduction of major...

  • Nesiritide for secondary pulmonary hypertension in patients with end-stage heart failure. O'Dell, Kate M.; Kalus, James S.; Kucukarslan, Suzan; Czerska, Barbara // American Journal of Health-System Pharmacy;3/15/2005, Vol. 62 Issue 6, p606 

    Purpose. The impact of adding nesiritide to standard therapy and positive inotropic agents in patients with end-stage heart failure and secondary pulmonary hypertension (PH) was studied. Methods. Patients included in this retrospective study were 18 years of age or older, admitted to the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics